- Home
- RIGL vs YALA Comparison
RIGL vs YALA Comparison
Compare RIGL & YALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | YALA |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United Arab Emirates |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 844.2M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RIGL | YALA |
|---|---|---|
| Price | $49.17 | $5.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $63.00 | $7.28 |
| AVG Volume (30 Days) | 194.5K | ★ 256.0K |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 5.20% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | $3.89 | $0.00 |
| Revenue Next Year | $21.95 | $12.03 |
| P/E Ratio | $36.91 | ★ $8.76 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $5.01 |
| 52 Week High | $52.24 | $7.83 |
Technical Indicators
Market Signals| Indicator | RIGL | YALA |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 55.50 |
| Support Level | $33.93 | $5.22 |
| Resistance Level | $49.50 | $5.63 |
| Average True Range (ATR) | 1.86 | 0.10 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 74.01 | 75.86 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.